MedStar Research Institute
MedStar Research Institute
News Article | August 3, 2017
MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer COLUMBIA, MD--(Marketwired - August 03, 2017) - MedStar Health is pleased to announce a collaboration with Indivumed, GmbH, a Germany-based oncology research company, to individualize anti-cancer medical therapies through state-of-the-art biospecimen collection, preservation and analysis. MedStar cares for thousands of cancer patients and survivors through the MedStar Health Cancer Network. In collaboration with the MedStar Health Research Institute, MedStar is increasing biospecimen collection started nearly a decade ago at Georgetown University's Lombardi Comprehensive Cancer Center. Over the term of the agreement, the cancer biobank will encompass MedStar's most active cancer programs throughout the system to partner with Indivumed's global annotated cancer biobank of human tumor tissue samples used to develop anti-tumor drugs and personalized medicine for cancer. This international partnership will allow MedStar researchers to access highest quality biospecimens and associated clinical data contributed by consenting patients. In addition, MedStar cancer researchers will have access to samples contributed by more than 30,000 patients within Indivumed's global cancer database operating within Europe, Asia and the United States. "By participating in the Indivumed global network, we'll have access to a critical mass of biological samples and clinical data for use in unique research for our community," said Neil Weissman, MD, president of the MedStar Health Research Institute. "Indivumed is a world leader in tissue collection and preservation and will expand our ability to conduct metabolic, as well as gene-based, cancer research." MedStar's Cancer Network has recently been granted a three-year accreditation with Commendation from the Commission on Cancer (CoC) of the American College of Surgeons (ACoS). In addition, the Georgetown University Lombardi Cancer Center holds the distinction of being a National Cancer Institute-designated Comprehensive Cancer Center, the only cancer center in the Washington area with such distinction. Louis M. Weiner, MD, director of Georgetown Lombardi and Director of MedStar's integrated cancer network stated firmly that, "the MedStar Cancer Network and Georgetown Lombardi are committed to delivering the highest standards of care and providing access to the most current cutting edge research for our patients suffering from this horrendous disease." Weiner continued, "the Indivumed cancer biobank has been and will continue to be a critical asset to our physicians and researchers in their quest to defeat cancer." Under an initial multi-year agreement, MedStar will collect lung, breast, colorectal, pancreatic and other cancer tissues at its most active cancer programs throughout the system for research and storage according to Indivumed's unique biobanking standard. Tissue collection at Georgetown Lombardi will continue pursuant to Georgetown University's existing agreement with Indivumed. The MedStar Health Research Institute is the research arm of MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region. MHRI provides scientific, administrative and regulatory support for research programs throughout the MedStar Health system. MHRI's expertise includes translational research into disease prevention, diagnosis and treatment. These programs complement the key clinical services and teaching programs in the 10 MedStar hospitals and other MedStar entities. For more information, visit www.MedStarResearch.org. MedStar Health is a not-for-profit health system dedicated to caring for people in Maryland and the Washington, D.C. region, while advancing the practice of medicine through education, innovation and research. MedStar's 30,000 associates, 6,000 affiliated physicians, 10 hospitals, ambulatory care and urgent care centers, and the MedStar Health Research Institute are recognized regionally and nationally for excellence in medical care. As the medical education and clinical partner of Georgetown University, MedStar trains more than 1,100 medical residents annually. MedStar Health's patient-first philosophy combines care, compassion and clinical excellence with an emphasis on customer service. For more information, visit www.MedStarHealth.org.
News Article | June 27, 2017
HYATTSVILLE, MD--(Marketwired - June 27, 2017) - MedStar Health Research Institute and MedStar Washington Hospital Center, in partnership with Healwell, are the recipients of a Palmer Foundation grant to study and compare effective dosages of massage therapy on pain and distress relief for hospitalized palliative care patients. The primary investigator of the grant is Hunter Groninger, MD, FACP, FAAHPM. Dr. Groninger serves as MedStar Washington Hospital Center's director of Palliative Care, where he conducts patient care, teaches, and participates in research activities. The interdisciplinary Palliative Care team takes a holistic approach to care that emphasizes the physical, emotional, social and spiritual needs of patients at any stage of serious illness, and provide services simultaneously with life-prolonging treatments. The research funded will investigate massage therapy as a cost-effective alternative or supplement to pharmacologic therapy for palliative care patients. Over one year of data collection, the study will seek to measure three strategies of massage therapy for patients. Its aim is to establish metrics for therapeutic massage dosing to reduce palliative care pain and distress, which are also cost-effective. Outcomes will be measured through a comparison of baseline surveys, interventions, and post-intervention surveys, with additional data being collected through a Patient Satisfaction Survey. "This study builds on existing palliative care research addressing nonpharmacologic supportive care for the seriously ill," said Dr. Groninger. "As a result of increasing patient and regulatory demand for integrative nonpharmacologic therapies, healthcare systems are being compelled to investigate optimal dosing of nonpharmacologic symptom-directed interventions, such as massage therapy that provide clinicians viable cost-effective options for pain/symptom distress management." Healwell is an Arlington, Va.-based non-profit agency whose mission is to improve the quality of life for people affected by acute, chronic, and terminal illness through integrative hands-on therapies, education, and research. Over the past 25 years, The Palmer Foundation has awarded hundreds of domestic grants to 501(c)(3) nonprofit organizations, primarily in Midwestern and Mid-Atlantic states, as well as international grants to worthwhile organizations working in countries where family members have lived. The Foundation currently focuses its grantmaking in the areas of youth empowerment, the environment, and public health. The MedStar Health Research Institute is the research arm of MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region. MHRI provides scientific, administrative and regulatory support for research programs throughout the MedStar Health system. MHRI's expertise includes translational research into disease prevention, diagnosis and treatment. These programs complement the key clinical services and teaching programs in the 10 MedStar hospitals and other MedStar entities. For more information, visit www.MedStarResearch.org. MedStar Health is a not-for-profit health system dedicated to caring for people in Maryland and the Washington, D.C. region, while advancing the practice of medicine through education, innovation and research. MedStar's 30,000 associates, 6,000 affiliated physicians, 10 hospitals, ambulatory care and urgent care centers, and the MedStar Health Research Institute are recognized regionally and nationally for excellence in medical care. As the medical education and clinical partner of Georgetown University, MedStar trains more than 1,100 medical residents annually. MedStar Health's patient-first philosophy combines care, compassion and clinical excellence with an emphasis on customer service. For more information, visit MedStarHealth.org.
Umans J.G.,MedStar Research Institute
Clinical journal of the American Society of Nephrology : CJASN | Year: 2012
Preeclampsia, a common and potentially devastating multisystem disorder unique to human pregnancy, represents a novel form of secondary hypertension with complex renal and systemic effects. Recent translational and clinical research reveals key pathophysiologic contributions due to dysregulation of angiogenic factors and of angiotensin signaling. Despite these insights, there are still difficulties in the clinical definition of preeclampsia and in the diagnosis of women with this disorder. Although recent research suggests the potential for new preventive and treatment strategies, most have not yet been shown ready for clinical use.
Brewer Jr. H.B.,MedStar Research Institute
Journal of Clinical Endocrinology and Metabolism | Year: 2011
Context: Statin treatment of cardiovascular patients reduces clinical events by 25 to 45%. Highdensity lipoprotein (HDL) has been proposed as a therapeutic target to further reduce this residual cardiovascular risk. Evidence Acquisition: PubMed from 1940 to the present was searched for all relevant citations related to the structure, function, and role of HDL in atherosclerosis. Evidence Synthesis: Epidemiological data, animal models with increased plasma HDL levels, as well as initial clinical and cardiovascular imaging trials suggest that increasing HDL in clinical patients will decrease the risk of cardiovascular disease. Proposed mechanisms by which HDL may reduce atherosclerosis include facilitating cholesterol efflux from cholesterol-loaded foam cells, role as an antiinflammatory lipoprotein, decreasing atherogenic oxidized low-density lipoprotein, increasing nitric oxide synthesis, serving as a plasma transport lipoprotein for biologically important proteins, and as an antithrombotic agent. The identification of the major receptors, enzymes, cellular transporters, and plasma lipid transfer proteins has provided major new insights into the pathways for HDL metabolism and cholesterol transport as well as targets for future drug development to increase HDL. Conclusions: Clinical trials with new HDL-raising drugs are currently under way to provide definitive evidence that increasing HDL will reduce cardiovascular events. The marked increase in our knowledge of the roles of HDL in cholesterol transport and the development of atherosclerosis now provides the framework for a more effective assessment of the plasma level and the function of HDL in an individual patient, as well as the lipoprotein profile after new drugs that increase HDL. Copyright © 2011 by The Endocrine Society.
Shara N.M.,MedStar Research Institute
Nutrition, Metabolism and Cardiovascular Diseases | Year: 2010
Morbidity and mortality from cardiovascular disease (CVD) are rising among Middle Eastern women. Despite this threat, awareness and understanding of CVD are low and surveillance data are nonexistent for many populations in this region. In this review, the data available on CVD in Middle Eastern women will be generalized. Population-based studies in the Middle East have been sporadic and most have been cross-sectional with small samples. Many Middle Eastern countries lack reliable surveillance data regarding the prevalence and incidence of CVD and its risk factors in women. This information is crucial for monitoring the scope of the problem and for guiding intervention strategies. Because of the ethnic heterogeneity of this region and the rapidly changing lifestyles, well-designed, longitudinal, large-scale population-based studies that focus on CVD and its risk factors are needed in multiple areas of the Middle East. © 2010 Elsevier B.V.
MedStar Research Institute | Date: 2011-04-05
Described herein are conditioned medium and processed conditioned medium, each of which comprises secreted stem cell factors; compositions containing conditioned medium and/or processed conditioned medium and a delivery polymer. The conditioned medium, processed conditioned medium and compositions may be used to promote blood vessel growth and healing of injured tissues.
Genway Biotech Inc., Emory University and MedStar Research Institute | Date: 2012-03-01
This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individuals risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individuals risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody.
MedStar Research Institute and Georgetown University | Date: 2013-04-15
Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.
MedStar Research Institute and Georgetown University | Date: 2010-10-09
Described herein are homing polypeptides that home to atherosclerotic plaque(s) in mammals and nucleic acids that encode such polypeptides. Also described are methods for detecting and treating conditions or disorders associated with, or characterized, by elevated levels of homing polypeptides that home to atherosclerotic plaque and/or vulnerable plaque.
MedStar Research Institute | Date: 2013-09-06
A non-invasive system, and method for simple, quantitative screening for mTBI and other forms of mid cognitive impairment using a visuo-motor performance test (for example, a submaximal grip test) in response to visual feedback to quantitatively measure the intra-individual variability of performance metric for initial screening of patients with mild traumatic brain injury (mTBI), and other neurological disorders. The system and method can be administered in minutes, by any level of caregiver, in any environment including military in-the-field or sports on-field deployments, and is useful in screening those truly injured from those disguising or mimicking injury. In addition to screening, the system and method can be used to monitor and/or detect changes to intra-individual variability over time by comparison to a baseline, which in turn is helpful in determining estimated recovery trajectory or other related information.